Skip to main content
Fig. 4 | BMC Rheumatology

Fig. 4

From: Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study

Fig. 4

Clinical evaluation at 12 months after treatment initiation of the two drugs

Changes in (A) prednisolone dosage, (B) DAS28-CRP and (C) mHAQ responses from the drug initiation to 12 months after. In both drug groups, there was a significant change in prednisolone dosage, DAS28-CRP and mHAQ after 12 months of initiation, but no significant difference was observed between the two drugs (A, P = 0.057; B, P = 0.551; C, P = 0.488)

JAKi: Janus kinase inhibitor; ABT: abatacept; DAS28-CRP: disease activity score 28-C-reactive protein; mHAQ: modified health assessment questionnaire

Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us